Young Deok Kim

Young Deok Kim

Auto-generated profile, based on publicly available information

Young Deok Kim

Departments of Neurosurgery, Seoul National University Bundang Hospital, 82 Gumi-ro 173 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in Journal of Korean Neurosurgical Society
Verified
Journal Article
Open access
PDF file
BRBong-Gyu Ryu
Bong-Gyu Ryu
SLSi Un Lee
Si Un Lee
HSHwan Seok Shim
Hwan Seok Shim
JPJeong-Mee Park
Jeong-Mee Park
YLYong Jae Lee
Yong Jae Lee
COChang Wan Oh
Chang Wan Oh
Objective : To analyze the outcomes of coil embolization (CE) for unruptured intracranial aneurysm (UIA) according to region and hospital size based on National Health Insurance Service data in South Korea.Methods : The incidence of complications, including intracranial hemorrhage (ICRH) and cerebral infarction (CI), occurring within 3 months and the 1-year mortality rates in UIA patients who underwent CE in 2018 were analyzed. Hospitals were classified as tertiary referral general hospitals (TRGHs), general hospitals (GHs) or semigeneral hospitals (sGHs) according to their size, and the administrative districts of South Korea were divided into 15 regions.Results : In 2018, 8425 (TRGHs, 4438; GHs, 3617; sGHs, 370) CEs were performed for UIAs. Complications occurred in 5.69% of patients seen at TRGHs, 13.48% at GHs, and 20.45% at sGHs. The complication rate in TRGHs was significantly lower than that in GHs (p=0.039) or sGHs (p=0.005), and that in GHs was significantly lower than that in sGHs (p=0.030). The mortality rates in TRGHs, GHs, and sGHs were 0.81%, 2.16%, and 3.92%, respectively, with no significant difference. Despite no significant difference in the mortality rates, the complication rate significantly increased as the number of CE procedures per hospital decreased (p=0.001; rho=-0.635). Among the hospitals where more than 30 CEs were performed for UIAs, the incidence of CIs (p=0.096, rho=-0.205) and the mortality rates (3 months, p=0.048, rho=-0.243; 1 year, p=0.009, rho=-0.315) significantly decreased as the number of CEs that were performed increased and no significant difference in the incidence of post-CE ICRH was observed.Conclusion : The complication rate in patients who underwent CE for UIA increased as the hospital size and physicians’ experience in conducting CEs decreased. We recommend nationwide quality control policies CEs for UIAs.

16 June 2022 in Journal of Korean Neurosurgical Society
Verified
Journal Article
Open access
PDF file
SBSeung Pil Ban
Seung Pil Ban
OKO-Ki Kwon
O-Ki Kwon
YKYoung Deok Kim
Young Deok Kim
BKBum-Tae Kim
Bum-Tae Kim
JOJAE SANG OH
JAE SANG OH
KSKorean NeuroEndovascular Society
Korean NeuroEndovascular Society
Objective : Stent-assisted coil embolization (SAC) has been increasingly used to treat various types of intracranial aneurysms. Delayed thromboembolic complications are major concerns regarding this procedure, so dual antiplatelet therapy with aspirin and clopidogrel is needed. However, clinicians vary the duration of dual antiplatelet therapy after SAC, and no randomized study has been performed. This study aims to compare the safety and efficacy of long-term (12 months) dual antiplatelet therapy and shortterm dual antiplatelet therapy (6 months) after SAC for patients with unruptured intracranial aneurysms (UIAs).Methods : This is a prospective, randomized and multicenter trial to investigate the optimal duration of dual antiplatelet therapy after SAC in patients with UIAs. Subjects will receive dual antiplatelet therapy for 6 months (short-term group) or 12 months (longterm group) after SAC. The primary endpoint is the assessment of thromboembolic complications between 1 and 18 months after SAC. We will enroll 528 subjects (264 subjects in each group) and perform 1 : 1 randomization. This study will involve 14 topperforming, high-volume Korean institutions specializing in coil embolization.Results : The trial will begin enrollment in 2022, and clinical data will be available after enrollment and follow-up.Conclusion : This article describes that the aim of this prospective randomized multicenter trial is to compare the effect of short-term (6 months) and long-term (12 months) dual antiplatelet therapy on UIAs in patients undergoing SAC, and to find the optimal duration.

10 September 2024 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
SLSang Hyo Lee
Sang Hyo Lee
SBSeung Pil Ban
Seung Pil Ban
OKO-Ki Kwon
O-Ki Kwon
YKYoung Deok Kim
Young Deok Kim
YLYongjae Lee
Yongjae Lee
MKMin-Yong Kwon
Min-Yong Kwon
BACKGROUND AND PURPOSE: Swelling of the salivary glands, known as contrast-induced sialadenitis (CIS), is an adverse reaction to iodide contrast agents. However, the incidence and risk factors of CIS after therapeutic neuroendovascular procedures have not yet been established. MATERIALS AND METHODS: Demographic and procedural factors that may influence the development of CIS were retrospectively analyzed to identify the incidence and risk factors of this condition. A total of 780 patients who underwent therapeutic neuroendovascular procedures between January 1, 2022 and December 31, 2022 were investigated. The risk factors affecting CIS were analyzed using multivariate logistic regression, and the quantitative degree of association between the volume of contrast administered and occurrence of CIS was determined using the receiver operating characteristic (ROC) curve. RESULTS: The incidence of CIS after therapeutic neuroendovascular procedures was 4.2%. Multivariate logistic regression analysis showed that female sex (odds ratio [OR] = 4.420, 95% confidence interval [CI]: 1.377-14.190, p = 0.013), volume of contrast administered (OR = 1.007, 95% CI: 1.003-1.101, p < 0.001), and guiding catheter tip located within the external carotid artery (ECA) (OR = 8.701, 95% CI: 3.459-21.885, p < 0.001) were independently associated with CIS occurrence after therapeutic neuroendovascular procedures. The volume of contrast administered had an area under the ROC curve of 0.723 (95% CI:0.635-0.810; p < 0.001), and the optimal cut-off value of the volume of contrast administered was 205 cc (sensitivity: 0.49, specificity: 0.87). CONCLUSIONS: We observed CIS in 4.2% of our patients undergoing therapeutic neuroendovascular procedures. This represents a higher incidence than previously reported. Female sex, volume of contrast administered, and guiding catheter tip located within the ECA are associated with CIS incidence. ABBREVIATIONS: AUC = area under the ROC curve; BMI = body mass index; CIS = contrast-induced sialadenitis; ECA = external cerebral artery; GFR = glomerular filtration rate; ROC = receiver operating characteristic.

10 October 2025 in Neurosurgery
Verified
Journal Article
Closed access
SBSeung Pil Ban
Seung Pil Ban
OKO-Ki Kwon
O-Ki Kwon
YKYoung Deok Kim
Young Deok Kim
HSHwan Seok Shim
Hwan Seok Shim
SSSeung Bin Sung
Seung Bin Sung
YPYoungmi Park
Youngmi Park
BACKGROUND AND OBJECTIVES: Modified antiplatelet therapies in patients with high on-treatment platelet reactivity (HTPR) remains unknown in neurointerventional treatment. We aimed to compare the safety and effectiveness of two different modified antiplatelet therapies in patients with HTPR undergoing stent-assisted coil embolization for an unruptured intracranial aneurysm. METHODS: We conducted a prospective, randomized clinical trial. Participants with HTPR were randomly assigned (1:1) to the triple antiplatelet therapy (TAT, addition of cilostazol) or modified dual antiplatelet therapy (MDAT, switched from clopidogrel to low-dose prasugrel) group. The primary outcome was all-bleeding-events during the 90-day follow-up period. The secondary outcomes were thromboembolic events and changes in the P2Y12 reaction unit (PRU) value throughout the follow-up period. Intention-to-treat (ITT) and per-protocol (PP) analyses were performed. RESULTS: In total, 172 of the 198 participants maintained initial antiplatelet therapy for 90 days. There was no significant difference in the all-bleeding-event rate between the two groups, both in the ITT population (hazard ratio [HR], 0.77 [95% CI, 0.49-1.20]; P = .26) and the PP population (HR, 0.79 [95% CI, 0.50-1.30]; P = .34). The thromboembolic event rate did not differ between the 2 groups in either the ITT population (HR, 0.33 [95% CI, 0.03-3.20]; P = .34) or the PP population (HR, 0.42 [95% CI, 0.04-4.70]; P = .48). Compared with those in the TAT group, the PRU values in the MDAT group greatly decreased over time, particularly for PRU after loading. CONCLUSION: Among patients with HTPR who underwent stent-assisted coil embolization for an unruptured intracranial aneurysm, there was no significant difference between the TAT and MDAT groups regarding the risk of all bleeding events and thromboembolic events during the 90 days of follow-up.

31 December 2022 in Journal of Cerebrovascular and Endovascular Neurosurgery
Verified
Journal Article
Open access
PDF file
SSSeung Bin Sung
Seung Bin Sung
YKYoung Deok Kim
Young Deok Kim
SBSeung Pil Ban
Seung Pil Ban
YLYong Jae Lee
Yong Jae Lee
OKO-Ki Kwon
O-Ki Kwon
Objective: The trend in the initial severity of aneurysmal subarachnoid hemorrhage (SAH) is unclear. This study aimed to evaluate whether there was an improvement in the initial severity of SAH over time.Methods: From January 1, 2005, to December 31, 2020, we identified patients who visited the emergency department of our institution with SAH due to intracranial aneurysm rupture. We identified the Hunt Hess (HH) grade and modified Fisher grade of each patient from the medical records, and the Mann-Kendal method was used to estimate the trend of each grade system.Results: A total of 547 patients with SAH were identified. The mean age of the patients was 59.3 years (standard deviation (SD), 14.6). The mean aneurysm size was 6.9 mm (SD, 4.6 mm). The most frequent aneurysm location was the anterior communicating artery (28.7%). In the Mann-Kendal estimates for the analysis of the trend, there was no statistically significant grade throughout the HH and modified Fisher grades. Similarly, there was no improvement throughout all grades in the modified Fisher grade over time.Conclusions: The initial severity of SAH due to cerebral aneurysm rupture did not improve over time.

1 January 2022 in Journal of Korean Neurosurgical Society
Verified
Journal Article
Open access
PDF file
SBSeung Pil Ban
Seung Pil Ban
OKO-Ki Kwon
O-Ki Kwon
YKYoung Deok Kim
Young Deok Kim
Objective : Placement of a single transverse stent via the nondominant A1 across the anterior communicating artery (AComA) into the contralateral A2 can provide sufficient neck coverage for wide-necked bifurcation AComA aneurysms. The authors described the feasibility, safety and long-term outcomes of this technique.Methods : Between January 2015 and February 2018, placement of a single transverse stent via the nondominant A1 was attempted in 17 wide-necked bifurcation AComA aneurysms. The authors reviewed the medical records and radiological studies.Results : The technical success rate was 94.1% (16/17). Periprocedural thromboembolic complications occurred in one patient (6.3%) without permanent neurological deficits. The mean clinical follow-up duration was 39.9±9.8 months. No deaths or delayed thromboembolic complications occurred. The mean angiographic follow-up duration was 38.9±9.8 months. The immediate and final follow-up complete occlusion rates were 87.4 and 93.7%, respectively. There was no recanalization during the follow-up period.Conclusion : Placement of a single transverse stent via the nondominant A1 across the AComA into the contralateral A2 is a feasible and relatively safe endovascular technique for the treatment of wide-necked bifurcation AComA aneurysms, with good long-term occlusion rates and a reasonable complication rate, if only the nondominant A1 is applicable.